ASST

ANALYST NOTE: ASST (Strive, Inc.) Date: 2026-08-28 Event Date: 2026-08-28

1. Structural Readiness

The setup is a confirmed coil. The breakout has fired, and the structure is active.

• Conservative Entry: $21.39
• Current Price: $23.12
• Extension: +8.1% above conservative entry.
• Volatility Context: The ATR at breakout was 6.1% (very high), and the current ATR is 6.2% (very high). This indicates elevated structural volatility and aggressive positioning by the market.
• Status: The setup is confirmed. The stock is trading in an extension phase relative to the initial entry point. The presence of a confirmed coil provides a partial positive readiness signal, indicating that the base formation was successful and the breakout momentum is currently active.

2. The Thesis Layer

This is a TACTICAL, setup-led name. There is no named secular thesis attached to this setup at this date. The conviction must be derived strictly from the quality of the structural setup and the immediate business fundamentals reported as of the event date. We do not invent a macro thesis; we judge the name on the strength of the breakout structure and the verifiable data points provided in the filings.

3. The Business

Strive, Inc. operates as a structured finance company and institutional asset manager with a diversified portfolio that has recently expanded into medical device operations and maintains a significant digital asset treasury.

• Asset Management & AUM: As of June 30, 2026, the Company manages over $2.8 billion in assets under management (AUM), an increase from over $2.4 billion as of December 31, 2025 (Evidence E1, E9).
• Digital Asset Treasury: The Company holds a substantial position in Bitcoin. As of June 30, 2026, digital assets totaled approximately $1.2 billion in fair value, consisting of 19,864 Bitcoin (Evidence E4). During the second quarter of 2026 alone, the Company acquired 6,236 Bitcoin at an average cost of $74,290 per coin (Evidence E3).
• Medical Device Operations: Through the consummation of the Semler Scientific Merger in early 2026, Strive acquired all assets and liabilities of Semler Scientific, including its medical device operations (Evidence E7). This segment generated $1.4 million in revenue for the three months ended June 30, 2026 (Evidence E2). The subsidiary markets the patented, FDA-cleared QuantaFlo vascular testing product, which has been integrated into healthcare insurance plans, delivery networks, and hospitals (Evidence E11, E12).
• Capital Formation: The Company has been active in raising capital. During the three months ended June 30, 2026, it issued 12.8 million shares of Class A common stock for $211.3 million and 3,456,308 shares of SATA Stock (preferred) for $345.7 million under at-the-market programs (Evidence E5, E6).
• Liquidity: As of August 7, 2026, cash and cash equivalents totaled $154.9 million, with a position in STRC Stock valued at $48.0 million (Evidence E8).

4. Archetype and Conviction

Archetype: Growth Leader / Capital Allocator Strive fits the archetype of a capital allocator aggressively expanding its balance sheet through both organic acquisition (medical devices) and strategic accumulation of digital assets (Bitcoin). The business model relies on disciplined capital allocation to drive long-term value creation (Evidence E16).

Conviction Factors:

• Evidence Quality: High. The evidence base is robust, with multiple SEC filings from August 10, 2026, confirming specific AUM growth, Bitcoin acquisition volumes, and revenue from the new medical segment.
• Structural Quality: The ATR at breakout (6.1%) and current ATR (6.2%) fall into the very high bucket. While this indicates elevated volatility, it also suggests strong market participation and a lack of "weak" consolidation. The setup is confirmed, not forming.
• Rerating Potential: The market appears to be reacting to the CEO's public declaration that the Bitcoin bear market is over (Evidence E17) and the aggressive accumulation of Bitcoin at lower average costs ($74,290 vs. prior year average of $113,153) (Evidence E3, E13).
• Management Expectations: Management has guided that the asset-management segment is expected to operate within a single-digit-million dollar operating loss to single-digit-million dollar operating profit range beginning in fiscal year 2026 (Evidence E10).

Valuation Context: The stock is trading at a premium to its conservative entry, reflecting the market's pricing of the Bitcoin accumulation strategy and the new medical revenue stream. The consensus price target of $28.00 (Evidence E20) suggests the market sees further upside, though the current price of $23.12 is already extended.

5. Invalidating Factors and Gaps

What would Strengthen the Case:

• Continued growth in AUM beyond the $2.8 billion reported in Q2 2026.
• Sustained revenue growth in the Semler Scientific medical device segment beyond the $1.4 million quarterly run rate.
• Further accumulation of Bitcoin at prices significantly below the current fair value, reinforcing the "buy the dip" narrative.

What would Invalidate the Case:

• A significant decline in the fair value of the Bitcoin treasury that erodes the $1.2 billion asset base reported in Q2 2026.
• Failure to achieve the projected single-digit-million dollar operating profit/loss range for the asset management segment.
• A reversal in the "Bitcoin bear market over" narrative leading to a sharp contraction in the stock's premium.

Gaps in Evidence:

• Detailed Margins: While revenue for the medical segment is provided ($1.4M), specific gross margin data for the medical device operations is not explicitly detailed in the provided evidence.
• Debt Structure: The evidence highlights equity issuance but does not explicitly detail the total debt load or interest coverage ratios as of August 2026.
• Long-term Bitcoin Cost Basis: While Q2 2026 acquisition costs are known, the blended cost basis of the entire 19,864 Bitcoin holding is not explicitly stated, only the Q2 average ($74,290) and the 2025 average ($113,153).

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Confirmed coil breakout with +8.1% extension; Q2 2026 AUM growth to $2.8B and $1.2B Bitcoin treasury; aggressive Bitcoin accumulation at $74,290 average cost. Key risks: Very high ATR (6.2%) indicating elevated volatility and potential for sharp mean reversion; reliance on Bitcoin price appreciation for asset value; dilution from recent equity issuance ($211.3M common + $345.7M preferred). Rating boundary: This is rated Buy rather than Strong Buy because the stock is already +8.1% extended from the conservative entry with very high volatility, suggesting the immediate low-risk entry window has passed. It is not rated Speculative because the setup is confirmed, the business fundamentals (AUM, Bitcoin holdings, new revenue) are robust and verified by recent filings, and the thesis is supported by management's active capital allocation. Sizing hint: Position size should be calibrated to the very high ATR; reduce size relative to a standard setup to account for the 6.2% daily volatility. Expected path: If the Bitcoin thesis holds and the medical segment scales, the stock may test the $28.00 consensus target, though volatility will likely remain elevated. Expected horizon: 3 to 6 months, contingent on the stability of the Bitcoin price and the execution of the asset management segment's profitability guidance. Failure mode to watch: A sharp decline in Bitcoin prices that triggers a revaluation of the $1.2B treasury, causing a rapid contraction in the stock price.